What’s driving Australia’s rechargeable sacral nerve stimulators market?

Australia accounts for approximately 30% of the Asia Pacific neuromodulation sector.

The ageing population, rising cases of neurological disorders, and an increasing incidence of urinary incontinence are driving Australia’s rechargeable sacral nerve stimulators (SNS) market, which is projected to witness a compound annual growth rate of 3% through 2033.

A GlobalData report revealed that Australia accounts for approximately 30% of the Asia Pacific neuromodulation market in 2024 amidst the rising demand.

A notable development in the SNS sector is the regulatory approval of the Axonics R20 rechargeable sacral neuromodulation system, with sales expected to start in November.

GlobalData Medical Devices Analyst Jyoti Sharma said that rechargeable sacral neuromodulation devices reduce the need for frequent replacements, helping to lower healthcare costs and improve patient satisfaction.

“As the market continues to evolve, it will offer significant opportunities for further advancements in treatment options,” Sharma said.